These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 20852752)
41. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician. Franz M; Ranger J; Hanewald B; Gallhofer B; Lay B Pharmacopsychiatry; 2012 Nov; 45(7):261-8. PubMed ID: 22648306 [TBL] [Abstract][Full Text] [Related]
42. Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006. Wu CS; Lin YJ; Feng J Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):989-96. PubMed ID: 22416032 [TBL] [Abstract][Full Text] [Related]
43. [The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group]. Yoshio T Seishin Shinkeigaku Zasshi; 2012; 114(6):690-5. PubMed ID: 22844820 [TBL] [Abstract][Full Text] [Related]
44. A prospective observational study of medication errors in general medicine department in a tertiary care hospital. Karthikeyan M; Lalitha D Drug Metabol Drug Interact; 2013; 28(1):13-21. PubMed ID: 23314531 [TBL] [Abstract][Full Text] [Related]
45. Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. Baandrup L; Allerup P; Nordentoft M; Lublin H; Glenthoj BY J Clin Psychiatry; 2010 Nov; 71(11):1457-64. PubMed ID: 21034689 [TBL] [Abstract][Full Text] [Related]
46. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Shinfuku N; Yang SY; Chong MY; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Dixon LB; Kreyenbuhl JA; Tan CH Aust N Z J Psychiatry; 2011 Nov; 45(11):968-75. PubMed ID: 21888603 [TBL] [Abstract][Full Text] [Related]
47. The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients. Andersen SE; Johansson M; Manniche C Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):75-81. PubMed ID: 18346047 [TBL] [Abstract][Full Text] [Related]
48. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. Deb S; Unwin G; Deb T J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426 [TBL] [Abstract][Full Text] [Related]
50. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong KH; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N Pharmacopsychiatry; 2012 Jan; 45(1):7-12. PubMed ID: 21989602 [TBL] [Abstract][Full Text] [Related]
51. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Owen RR; Fischer EP; Kirchner JE; Thrush CR; Williams DK; Cuffel BJ; Elliott CE; Booth BM Am J Med Qual; 2003; 18(4):140-6. PubMed ID: 12934949 [TBL] [Abstract][Full Text] [Related]
52. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. Farriols C; Ferrández O; Planas J; Ortiz P; Mojal S; Ruiz AI J Pain Symptom Manage; 2012 May; 43(5):945-52. PubMed ID: 22436835 [TBL] [Abstract][Full Text] [Related]
53. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. Pai NB; Laidlaw M; Vella SC Acta Psychiatr Scand; 2012 Jul; 126(1):40-6. PubMed ID: 22432694 [TBL] [Abstract][Full Text] [Related]
54. [Basis of prescribing antipsychotics]. Sato S Seishin Shinkeigaku Zasshi; 2011; 113(10):1036-40. PubMed ID: 22187891 [TBL] [Abstract][Full Text] [Related]
55. Antipsychotic polypharmacy: a needle in a haystack? López de Torre A; Lertxundi U; Hernández R; Medrano J Gen Hosp Psychiatry; 2012; 34(4):423-32. PubMed ID: 22460003 [TBL] [Abstract][Full Text] [Related]
56. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Humberstone V; Wheeler A; Lambert T Aust N Z J Psychiatry; 2004 Apr; 38(4):240-5. PubMed ID: 15038803 [TBL] [Abstract][Full Text] [Related]
57. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883 [TBL] [Abstract][Full Text] [Related]
58. Diversity versus concentration in antipsychotic drug selection. Leslie DL; Rosenheck RA J Ment Health Policy Econ; 2008 Sep; 11(3):107-12. PubMed ID: 18806300 [TBL] [Abstract][Full Text] [Related]
59. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Hazra M; Uchida H; Sproule B; Remington G; Suzuki T; Mamo DC Psychiatry Clin Neurosci; 2011 Dec; 65(7):676-8. PubMed ID: 22176287 [TBL] [Abstract][Full Text] [Related]
60. Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study. Xue Q; Xiong X; Feng Y; Yao L; Chen S; Xiang L Int Clin Psychopharmacol; 2014 Sep; 29(5):288-95. PubMed ID: 24323200 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]